On April 20th, Ispire Technology Inc. (NASDAQ: ISPR) announced the establishment of a strategic partnership with international cannabis brand, Cookies.
According to the terms of their supply agreement, Ispire will supply a total of 15 million CBD products to Cookies' third-party retail and wholesale partners. Ispire will also provide a dedicated product team to support Cookies' product requirements.
In 2010, Cookies was founded as a brand for cannabis products under NOYA and is headquartered in San Francisco, USA. The company offers over 70 proprietary cannabis strains and more than 2000 products. In 2018, it opened its first retail store in Los Angeles and since then has expanded to over 50 retail locations across 17 markets in 5 countries. AdAge has named Cookies as one of the hottest brands in the US for 2021, making it the first cannabis brand to receive this honor. Cookies was founded by Gilbert Anthony Milam, now known as Berner, a rapper with 46 albums to his name.
Related Reading:
Rhein Biotech has raised $1.5 million in Ispire's first public offering of stock.
CBD manufacturer Ispire successfully completed its initial public offering, raising $18.9 million in funding.
CBD manufacturer, Ispire, has announced the pricing of its initial public offering at $7 per share, with a total issuance of 2.7 million shares.
Ispire has decided to halve the size of its planned initial public offering (IPO) but will maintain the share price at $6 to $8 per share.
Reference sources:
Ispire Technology Inc. has announced a strategic partnership with the global cannabis lifestyle brand Cookies.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
